(VIANEWS) – The Market ended the session with ULTIMOVACS (ULTI.OL) jumping 26.4% to kr11.06 on Wednesday while Oslo Børs Benchmark Index_GI rose 0.48% to kr1,349.28.
ULTIMOVACS’s last close was kr8.75, 95.1% under its 52-week high of kr178.60.
About ULTIMOVACS
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers. Its lead product candidate is UV1, a peptide-based cancer vaccine that induces a specific T cell response against the universal cancer antigen telomerase. The company was incorporated in 2011 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, ULTIMOVACS has a trailing twelve months EPS of kr-5.5.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -51.94%.
Yearly Top and Bottom Value
ULTIMOVACS’s stock is valued at kr11.06 at 22:30 EST, way below its 52-week high of kr178.60 and way above its 52-week low of kr6.07.
Moving Average
ULTIMOVACS’s worth is way below its 50-day moving average of kr106.48 and way under its 200-day moving average of kr97.64.
Volatility
ULTIMOVACS’s last week, last month’s, and last quarter’s current intraday variation average was a positive 9.79%, a negative 0.65%, and a positive 3.55%.
ULTIMOVACS’s highest amplitude of average volatility was 9.79% (last week), 6.29% (last month), and 3.55% (last quarter).
Volume
Today’s last reported volume for ULTIMOVACS is 6394220 which is 513.6% above its average volume of 1042080.
More news about ULTIMOVACS (ULTI.OL).
